These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 21052011)
1. Simvastatin reduces lipoprotein-associated phospholipase A2 in lipopolysaccharide-stimulated human monocyte-derived macrophages through inhibition of the mevalonate-geranylgeranyl pyrophosphate-RhoA-p38 mitogen-activated protein kinase pathway. Song JX; Ren JY; Chen H J Cardiovasc Pharmacol; 2011 Feb; 57(2):213-22. PubMed ID: 21052011 [TBL] [Abstract][Full Text] [Related]
2. Simvastatin antagonizes tumor necrosis factor-alpha inhibition of bone morphogenetic proteins-2-induced osteoblast differentiation by regulating Smad signaling and Ras/Rho-mitogen-activated protein kinase pathway. Yamashita M; Otsuka F; Mukai T; Otani H; Inagaki K; Miyoshi T; Goto J; Yamamura M; Makino H J Endocrinol; 2008 Mar; 196(3):601-13. PubMed ID: 18310456 [TBL] [Abstract][Full Text] [Related]
3. [Simvastatin suppress lipopolysaccharides induced upregulation of lipoprotein associated phospholipase A(2) expression in macrophages via inactivation of p38MAPK pathway]. Jin WY; Ren JY; Chen H Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Oct; 38(10):923-8. PubMed ID: 21176638 [TBL] [Abstract][Full Text] [Related]
4. Simvastatin suppresses self-renewal of mouse embryonic stem cells by inhibiting RhoA geranylgeranylation. Lee MH; Cho YS; Han YM Stem Cells; 2007 Jul; 25(7):1654-63. PubMed ID: 17464088 [TBL] [Abstract][Full Text] [Related]
5. Simvastatin reduces human atrial myofibroblast proliferation independently of cholesterol lowering via inhibition of RhoA. Porter KE; Turner NA; O'Regan DJ; Balmforth AJ; Ball SG Cardiovasc Res; 2004 Mar; 61(4):745-55. PubMed ID: 14985071 [TBL] [Abstract][Full Text] [Related]
6. Dipyridamole activation of mitogen-activated protein kinase phosphatase-1 mediates inhibition of lipopolysaccharide-induced cyclooxygenase-2 expression in RAW 264.7 cells. Chen TH; Kao YC; Chen BC; Chen CH; Chan P; Lee HM Eur J Pharmacol; 2006 Jul; 541(3):138-46. PubMed ID: 16765938 [TBL] [Abstract][Full Text] [Related]
7. OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways. Wang WY; Li J; Yang D; Xu W; Zha RP; Wang YP Cardiovasc Res; 2010 Mar; 85(4):845-52. PubMed ID: 19910444 [TBL] [Abstract][Full Text] [Related]
8. Decreased C-reactive protein-induced resistin production in human monocytes by simvastatin. Hu WL; Qiao SB; Li JJ Cytokine; 2007 Dec; 40(3):201-6. PubMed ID: 18023360 [TBL] [Abstract][Full Text] [Related]
9. RhoA and p38 MAPK mediate apoptosis induced by cellular cholesterol depletion. Calleros L; Lasa M; Rodríguez-Alvarez FJ; Toro MJ; Chiloeches A Apoptosis; 2006 Jul; 11(7):1161-73. PubMed ID: 16699960 [TBL] [Abstract][Full Text] [Related]
10. Simvastatin attenuates lipopolysaccharide-induced airway mucus hypersecretion in rats. Ou XM; Wang BD; Wen FQ; Feng YL; Huang XY; Xiao J Chin Med J (Engl); 2008 Sep; 121(17):1680-7. PubMed ID: 19024099 [TBL] [Abstract][Full Text] [Related]
11. Simvastatin inhibits C-reactive protein-induced pro-inflammatory changes in endothelial cells by decreasing mevalonate pathway products. Liang YJ; Shyu KG; Wang BW; Lai LP Cardiology; 2008; 110(3):182-90. PubMed ID: 18057884 [TBL] [Abstract][Full Text] [Related]
12. Simvastatin attenuates formalin-induced nociceptive behaviors by inhibiting microglial RhoA and p38 MAPK activation. Chen XY; Li K; Light AR; Fu KY J Pain; 2013 Nov; 14(11):1310-9. PubMed ID: 23900131 [TBL] [Abstract][Full Text] [Related]
13. Modulation of COX-2 expression by statins in human monocytic cells. Habib A; Shamseddeen I; Nasrallah MS; Antoun TA; Nemer G; Bertoglio J; Badreddine R; Badr KF FASEB J; 2007 Jun; 21(8):1665-74. PubMed ID: 17317725 [TBL] [Abstract][Full Text] [Related]
14. High density lipoprotein suppresses lipoprotein associated phospholipase A2 in human monocytes-derived macrophages through peroxisome proliferator-activated receptor-γ pathway. Han GP; Ren JY; Qin L; Song JX; Wang L; Chen H Chin Med J (Engl); 2012 Dec; 125(24):4474-80. PubMed ID: 23253723 [TBL] [Abstract][Full Text] [Related]
15. Simvastatin inhibits MMP-9 secretion from human saphenous vein smooth muscle cells by inhibiting the RhoA/ROCK pathway and reducing MMP-9 mRNA levels. Turner NA; O'Regan DJ; Ball SG; Porter KE FASEB J; 2005 May; 19(7):804-6. PubMed ID: 15728660 [TBL] [Abstract][Full Text] [Related]
16. HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C Biochem Biophys Res Commun; 2008 Sep; 374(2):309-14. PubMed ID: 18625202 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. Merrell MA; Wakchoure S; Lehenkari PP; Harris KW; Selander KS Eur J Pharmacol; 2007 Sep; 570(1-3):27-37. PubMed ID: 17640631 [TBL] [Abstract][Full Text] [Related]
18. Inhibition of the RhoA/Rho-associated, coiled-coil-containing protein kinase-1 pathway is involved in the therapeutic effects of simvastatin on pulmonary arterial hypertension. Liu WH; Xu XH; Luo Q; Zhang HL; Wang Y; Xi QY; Zhao ZH; Liu ZH Clin Exp Hypertens; 2018; 40(3):224-230. PubMed ID: 29319354 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of RhoA/Rho-kinase pathway suppresses the expression of type I collagen induced by TGF-beta2 in human retinal pigment epithelial cells. Itoh Y; Kimoto K; Imaizumi M; Nakatsuka K Exp Eye Res; 2007 Mar; 84(3):464-72. PubMed ID: 17217948 [TBL] [Abstract][Full Text] [Related]
20. Statins suppress THP-1 cell migration and secretion of matrix metalloproteinase 9 by inhibiting geranylgeranylation. Wong B; Lumma WC; Smith AM; Sisko JT; Wright SD; Cai TQ J Leukoc Biol; 2001 Jun; 69(6):959-62. PubMed ID: 11404382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]